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The pharmacokinetics of some β-blockers are altered by cardiopulmonary bypass (CPB). The objective of this study was to
compare the effect of coronary artery bypass graft (CABG) surgery employing CPB on the pharmacokinetics of propranolol and
atenolol. We studied patients receiving oral propranolol with doses ranging from 80 to 240 mg (N = 11) or atenolol with doses
ranging from 25 to 100 mg (N = 8) in the pre- and postoperative period of CABG with moderately hypothermic CPB (32°C). On
the day before and on the first day after surgery, blood samples were collected before β-blocker administration and every 2 h
thereafter. Plasma levels were determined using high-performance liquid chromatography and data were treated by pharmaco-
kinetics-modelling. Statistical analysis was performed using ANOVA or the Friedman test, as appropriate, and P < 0.05 was
considered to be significant. A prolongation of propranolol biological half-life from 5.41 ± 0.75 to 11.46 ± 1.66 h (P = 0.0028) and
an increase in propranolol volume of distribution from 8.70 ± 2.83 to 19.33 ± 6.52 L/kg (P = 0.0032) were observed after CABG
with CPB. No significant changes were observed in either atenolol biological half-life (from 11.20 ± 1.60 to 11.44 ± 2.89 h) or
atenolol volume of distribution (from 2.90 ± 0.36 to 3.83 ± 0.72 L/kg). Total clearance was not changed by surgery. These CPB-
induced alterations in propranolol pharmacokinetics may promote unexpected long-lasting effects in the postoperative period
while the effects of atenolol were not modified by CPB surgery.
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Introduction
Several β-adrenoreceptor antagonists (β-blockers) have
been used for the treatment of angina, and the choice
depends on the selectivity in relation to the type of β-
receptors, antiarrhythmic actions, intrinsic sympathomi-
metic activity, potency, lipid solubility, blocking of α-adre-
noceptors, oxidation phenotype, effects on serum lipids,
and membrane-stabilizing activity (1). β-adrenoreceptor
antagonists improve acute outcomes and long-term prog-
nosis in ischemic heart disease (2) and reduce periopera-
tive events among high-risk patients undergoing major
non-cardiac and vascular surgery (3,4). Preoperative β-
blocker therapy has also been shown to reduce the inci-
dence of intraoperative ischemic events related to in-
creases in heart rate and hemodynamic responses to
surgical stimulation during coronary artery bypass graft
(CABG) (5,6). Administration of a β-blocker before coro-
nary bypass and its postoperative reinstitution is consid-
ered safe and beneficial (7,8), whereas an abrupt with-
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drawal of the drug has been associated with myocardial
ischemia, hypertension, and arrhythmia secondary to a β-
blockade-induced increase in β-receptor density (9).
In patients undergoing CABG, atenolol and proprano-
lol are commonly used β-blockers and the same drug is
usually reintroduced after surgery. Because it is known
that the dose of propranolol necessary to obtain an ad-
equate β-blockade effect in the postoperative period, in
order to reduce heart rate to <100 beats per minute (bpm),
is lower than the preoperative dose, we carried out a
clinical study (10) that showed that cardiopulmonary by-
pass (CPB) alters the kinetic disposition of propranolol in
patients undergoing cardiac surgery.
Since the same preoperative dose of atenolol and
propranolol is currently used to obtain the same degree of
β-blockade in the postoperative period, we compared the
pre- and postoperative pharmacokinetics of propranolol
and atenolol in patients with coronary heart disease under-
going coronary artery bypass grafting employing cardio-
pulmonary bypass under moderate hypothermia.
Material and Methods
The study protocol was approved by the Hospital Eth-
ics Committee, and written informed consent was obtained
from all patients. Patients scheduled for CABG under
moderate hypothermic CPB and receiving propranolol (N
= 11) or atenolol (N = 8) preoperatively were enrolled in the
study. Inclusion criteria were: a) left ventricular ejection
fraction greater than 0.5 and normal right ventricular func-
tion assessed by preoperative transthoracic echocardiog-
raphy in the week preceding surgery; b) normal hepatic
and renal function; c) patients with minimal or low surgical
risk according to Higgins score (11), as described below.
Patients with diabetes mellitus, chronic obstructive lung
disease, peripheric arterial vascular disease, or candi-
dates for off-pump CABG were excluded from the study.
Surgical risk was preoperatively assessed according to
the criteria proposed by Higgins et al. (11), i.e., patients
were classified into minimal, low, moderate, high, extreme
risk categories. This risk score takes into account the
following variables: a) emergency procedure, b) preopera-
tive serum creatinine levels, c) presence of left ventricular
dysfunction, d) preoperative hematocrit, e) age, f) chronic
pulmonary disease, g) prior vascular surgery, h) reopera-
tion, and i) mitral valve insufficiency. Partial results con-
cerning patients receiving propranolol have been already
reported elsewhere (10). Body surface area (BSA) and
lean body mass (LBM) were calculated using standard
formulas, as follows: BSA (m²) = ([height (cm) x weight
(kg)] / 3600)½; LBM men (kg) = (1.10 x weight (kg)) - 128
(weight2 / (100 x height (m))2) and LBM women (kg) = (1.07
x weight (kg)) - 148 (weight2 / (100 x height (m))2).
Monitoring, anesthetic and surgical procedures
Each patient received 0.1 to 0.2 mg/kg midazolam
orally 30 min before surgery. After the patient was admitted
into the surgical room, electrocardiographic monitoring
configured to continuously display the leads II and V5 and
pulse oximetry were installed. Invasive arterial pressure
monitoring was obtained in the left radial artery using a
specific 20-gauge radial catheter (Quickflash set, Arrow,
Germany). Anesthesia was induced with 0.3 to 0.5 μg/kg
sufentanil, 0.3 mg/kg midazolam and 0.1 to 0.2 mg/kg
pancuronium bromide and maintained by isoflurane inha-
lation and supplementary doses of sufentanil and pancu-
ronium bromide. During CPB, hypnosis was obtained us-
ing supplementary doses of midazolam. For each patient,
tidal volume was set at 8 mL/kg and the respiratory rate
was adjusted by the anesthesiologist in order to achieve
PaCO2 values between 30 and 35 mmHg. Inspiratory time
representing 33% of the respiratory cycle total time and an
inspired oxygen fraction of 0.60 were maintained through-
out surgery. Positive end expiratory pressure of 5 cm/H2O
was implemented after intubation and maintained through-
out surgery. After anesthetic induction, a nasopharyngeal
thermometer, a vesical catheter and a central venous
catheter (Multi Med central venous catheter, Edwards Life-
sciences, USA) were inserted. When judged necessary by
the attending anesthesiologist, a fiberoptic thermodilution
pulmonary artery catheter (CCO/SvO2/VIP™TD catheter,
Edwards Lifesciences) was inserted through the right in-
ternal jugular vein.
After opening the chest and dissection of the vascular
structures, cannulas were inserted into the aorta and the
inferior and superior cava veins. Cardiopulmonary bypass
was performed using an extracorporeal circuit and mem-
brane oxygenator primed with lactated Ringer solution
(Oxim II-34 Ultra membrane oxygenator, Edwards Life-
sciences). After initiation of CPB, patients were cooled and
core temperature was maintained at 32-34°C (89.6-93.2°F)
until the end of coronary grafting. After rewarming to 37°C
(98.6°F), the patients were weaned from CPB. Vasoactive
drugs were infused when judged necessary by the attend-
ing anesthesiologist. In case of bradycardia with heart rate
lower than 60 bpm, a pacemaker was installed to maintain
cardiac frequency in 80 bpm.
Study protocol and β-blocker measurements
All patients were chronically receiving β-blocker orally:
propranolol (Inderal®, Zeneca, Brazil), with total daily doses
ranging from 80 to 240 mg divided into 2-4 times a day or
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atenolol (Atenol®, Zeneca), with total daily doses ranging
from 25 to 100 mg divided into 1-2 times a day. Immedi-
ately before administration of the last preoperative dose of
β-blocker on the night before surgery, a blood sample was
collected to measure baseline propranolol or atenolol plas-
ma concentration. Then, the patients received propranolol
or atenolol according to their standard dose regimen and
other samples were drawn at 2, 4, 6, and 8 h for preopera-
tive pharmacokinetic modelling. Patients were operated
the following morning. Eighteen hours after the end of
surgery, on the first postoperative day, when the patients
were allowed to drink water, a postoperative baseline
blood sample was collected and the same preoperative β-
blocker was administered orally: 10 mg propranolol or 25
mg atenolol. To model postoperative pharmacokinetics,
blood samples were collected at 2, 4, 6, 8, 12, and 24 h.
EDTA tubes containing blood samples were centrifuged at
2800 g and stored at a temperature of -70°C (-158°F) until
measurement of the drug. Heart rate and mean arterial
pressure were recorded at admission to the operating
room, at the end of surgery, immediately after admission to
the intensive care unit, and at 8:00 am on the first and
second postoperative days.
Drug assay for propranolol was performed using high-
performance liquid chromatography with fluorescence de-
tection (HPLC-F) as described (12). Briefly, plasma pro-
pranolol concentration was determined by HPLC-F after a
clean up of plasma consisting of a single extraction, by
adding 200 μL 1.25 M NaOH to a glass tube containing 200
μL plasma plus an internal standard (verapamil hydrochlo-
ride, 2.5 mg/assay). The mixture was vortexed for 1 min,
followed by centrifugation at 2800 g for 10 min, and the
organic phase was immersed in a liquid nitrogen bath. The
supernatant was transferred to a conic glass tube and
dried to residue in a stream of nitrogen. The residue was
then dissolved in 100 μL of mobile phase and injected
(loop 20 μL) into HPLC-F Shimadzu LC-10A (Shimadzu
Corp., Japan), connected to a 4-micron reversed phase
column NovaPak™ C18, 150 x 3.9 mm, adapted to a C18
Nova Pack precolumn insert, 4 μm, 60A (Waters Corp.,
USA). The binary mobile phase consisting of 0.38 M ace-
tate buffer, pH 5.0, and acetonitrile (65:35, v/v) was deliv-
ered at 0.7 mL/min, isocratically. Peaks were monitored
using a fluorescence detector (RF 10 AXL, Shimadzu
Corp.) with 290 nm (λex) and 358 nm (λem). For the
determination of plasma atenolol levels, 200-μL plasma
aliquots were added to 100 μL of internal standard (1.25
μg/mL sotalol) in 2.0-mL Eppendorf tubes. Plasma pro-
teins were precipitated by the addition of 400 μL acetoni-
trile and homogenized in a tube shaker for 15 s. The tubes
were centrifuged at 5600 g for 30 min at 5°C, the superna-
tant was decanted, and the residue remaining in the tube
was discarded. Aliquots (200 μL) of the supernatant (or-
ganic-aqueous extract) were transferred to a conic tube
and the solvent was evaporated in a water bath under a
nitrogen flow at 37°C. The evaporation residue was dis-
solved in 200 μL of a mixture, water:methanol, 80:20, v/v,
and injected automatically into a Shimadzu liquid chro-
matograph equipped with an LC-10 AD VP pump con-
nected to a C18 Shim Pack column (150 x 4.6 mm, 4 μm;
Shimadzu) protected by a C18 Nova Pack precolumn
inserts (4 μm, 60A). For separation, a binary mobile phase
consisting of 50 mM phosphate buffer, pH 5.5, and metha-
nol (80:20, v/v) was used at 0.7 mL/min. The peaks were
monitored with an RF 10AXL fluorescence detector at
wavelengths of 235 nm (λex) and 290 nm (λem). The areas
of the peaks were integrated using the Class VP software
(Shimadzu) and a CR6A integrator (Shimadzu).
Propranolol and atenolol plasma levels were normal-
ized according to hematocrit values, considering the he-
modilution that occurs during CPB. For pharmacokinetics,
the software pharmacokinetics solution 2.0 (Pharmacoki-
netics and Metabolism Software, USA) was applied to
estimate the following main kinetic parameters: apparent
volume of distribution, total body clearance and biological
β half-life.
Statistical analysis
Statistical analysis was performed using the SAS sta-
tistical package (SAS Institute Inc., USA). Normal distribu-
tion of data was evaluated using the Shapiro-Wilk test and
graphic analysis of residual distribution observed by means
of normal probabilities graph and box-plot (13,14). If non-
normal data distribution was observed, the data were
analyzed using non-parametrical statistical tests. Patient
characteristics were compared using the chi-square test,
the Fisher exact test and the unpaired Student t-test, when
appropriate. After confirmation of normal distribution of the
β-blocker plasma concentrations and their logarithmic trans-
formation, pharmacokinetic data before and after surgery
in both groups were compared by two-way analysis of
variance for repeated measurements. If analysis detected
that effect of surgery with CPB on plasma concentrations
was different for atenolol and propranolol groups, a com-
parison of the logarithm of plasma concentration decay
slopes of both drugs estimated using a growing curves
model was performed in order to compare the behavior of
the groups. This type of analysis enabled the modeling of
the relationship between the observations made on the
same individual pre- and postoperatively.
The hemodynamic variables were compared between
the two groups using a two-way analysis of variance for
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repeated measurements. Post hoc analysis was performed
using the Student-Newman-Keuls test. Pharmacokinetic
parameters before and after surgery were compared by
the Friedman test and differences between groups were
compared using Wilcoxon tests. All data were reported as
mean ± standard deviation unless otherwise specified.
Statistical significance was considered to be P < 0.05.
Results
The characteristics of the patients enrolled in this study
are presented in Table 1. Briefly, no differences between
the groups were found regarding gender, age or anthropo-
metric measures. Both groups presented minimal or low
surgical risk according to criteria proposed by Higgins et al.
(11). All patients included in the study presented a normal
preoperative creatinine clearance (85.07 ± 11.59 mL/min
in the propranolol group and 83.37 ± 23.99 in the atenolol
group). Hepatic function assessed by the prothrombin time
was normal for both groups, with a mean of 13.59 s
(ranging from 11.7 to 16.1 s) for the propranolol group and
13.83 s (from 12.3 to 15.1 s) for the atenolol group. The
duration of surgery was greater for the propranolol group
but the duration of CPB was comparable in both groups as
well as minimal temperature achieved during CPB (Table
1). The degree of hemodilution during CPB indicated by
the fall in initial hematocrit from 40.1 ± 3.6 to 26.5 ± 4.6% in
the propranolol group and from 40.8 ± 2.3 to 26.6 ± 3.3% in
the atenolol group was also similar. Dobutamine infusion
in doses lower than 5.0 μg·kg-1·min-1 was necessary in 3
patients of the propranolol group and in 2 patients of the
atenolol group during the weaning from CPB. Nitroglycer-
ine and sodium nitroprusside were administered as neces-
sary for arterial pressure control. All patients achieved
hemodynamic stability in the immediate postoperative pe-
riod, permitting the weaning from vasoactive drugs within
18 h. As shown in the upper panel of Figure 1, there was an
increase in heart rate after CPB by the second postopera-
tive day, returning to preoperative baseline values immedi-
ately after patient admission to the operating room. No
significant differences were observed between groups.
Mean arterial pressure was lower immediately after CPB
returning to preoperative levels at the end of observation
time in both groups, without significant differences be-
tween them (lower panel of Figure 1). One patient of each
group presented acute atrial fibrillation after discharge
from the intensive care unit. No episodes of bradycardia
were observed during the study and there was no need for
postoperative pacemaker support. As shown in Table 1, no
differences were observed in the intensive care unit or
overall postoperative length of stay.
Table 1. Demographic and surgical data of the patients.
Propranolol Atenolol
group group
Gender (male/female) 7/4 6/2
Age (years) 57 ± 8 63 ± 7
Body weight (kg) 75.4 ± 11.9 76.2 ± 12.9
Height (m) 1.64 ± 0.08 1.65 ± 0.08
BSA (m2) 1.83 ± 0.19 1.86 ± 0.2
LBM (kg/m2) 28.0 ± 3.86 27.9 ± 3.93
Duration of surgery (min) 420 ± 47 365 ± 45*
Duration of CPB (min) 107 ± 32 82 ± 23
Minimal temperature on CPB (°C) 32.9 ± 2.3 32.4 ± 2.5
Minimal Ht on CPB (%) 26.5 ± 4.6 26.6 ± 3.3
ICU length of stay (h) 48 ± 15 47 ± 9
Postoperative length of stay (days) 5.8 ± 1 5.5 ± 0.6
BSA = body surface area; LBM = lean body mass; CPB =
cardiopulmonary bypass; Ht = hematocrit; ICU = intensive care
unit. *P < 0.05 compared to propranolol group (chi-square test
and unpaired t-test).
Figure 1. Heart rate and arterial pressure of patients receiving
atenolol and propranolol. The patients received atenolol (filled
circles, N = 8) or propranolol (open circles, N = 11). OR =
operating room; ICU = intensive care unit. POD1 and POD2 =
postoperative days 1 and 2, respectively.
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As can be seen in the adjusted model of growing curves
presented in the upper panel of Figure 2, the fall of preopera-
tive plasma levels of propranolol, shown as the descending
dashed slope, was significantly steeper than the fall in
Figure 2. Adjusted model of log plasma concentration of atenolol
(continuous line) and propranolol (dashed line) during the preop-
erative and postoperative periods of coronary artery bypass
graft surgery with cardiopulmonary bypass. The slopes of the
decaying phase of the log plasma concentration of atenolol pre-
and postoperatively were -0.08 and –0.11, respectively. For pre-
and postoperative decaying concentrations of propranolol, the
slopes were -0.16 and -0.08, respectively.
Table 2. Pharmacokinetics of propranolol and atenolol during the pre- and
postoperative periods of coronary artery bypass graft surgery with cardio-
pulmonary bypass.
Pharmacokinetic parameter Preoperative Postoperative
period period
Biologcial β half-life (h)
Atenolol (N = 8) 11.2 ± 4.5 11.4 ± 8.2
Propranolol (N = 11) 5.4 ± 2.5+ 11.5 ± 8.2*
Apparent volume of distribution (L/kg)
Atenolol (N = 8) 2.9 ± 1.0 3.8 ± 2.0
Propranolol (N = 11) 8.7 ± 9.4+ 19.3 ± 21.6+*
Total body clearance (mL·min-1·kg-1)
Atenolol (N = 8) 3.6 ± 1.8 4.7 ± 3.0
Propranolol (N = 11) 16.1 ± 14.3+ 17.2 ± 16.0+
+P < 0.05, significantly different compared to atenolol. *P < 0.05, significant-
ly different compared to preoperative period (two-way repeated measures
ANOVA followed by Student-Newmann-Keuls post-hoc test).
plasma levels of atenolol (-0.16 vs –0.08; P = 0.01). Con-
versely, on the first day following surgery, as presented in
the postoperative adjusted model of plasma concentration
(lower panel of Figure 2), the propranolol plasma decay
slope was similar to that presented for atenolol
(-0.08 vs –0.11). When pre- to postoperative phar-
macokinetic data from atenolol and propranolol
were compared, a 111% increase (from 5.4 ± 2.5
to 11.5 ± 8.2 h) in postoperative propranolol bio-
logical β half-life was observed while no alterations
were observed in atenolol biological β half-life
(from 11.2 ± 4.5 to 11.4 ± 8.1 h). The apparent
volume of distribution of propranolol significantly
increased by 121% in the first postoperative day
(from 8.7 ± 9.4 to 19.3 ± 21.6 L/kg) compared with
preoperative values while atenolol volume of dis-
tribution presented an increase of 31% (from 2.9 ±
1 to 3.8 ± 2 L/kg). No alterations were observed in
postoperative total body clearance for atenolol or
propranolol, as shown in Table 2. Furthermore, no
relationship was observed between the length of
CPB or esophageal temperature during CPB and
pharmacokinetic parameters.
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Discussion
In this study, a significant increase in the biological β
half-life and in the apparent volume of distribution of pro-
pranolol in patients undergoing surgery with hypothermic
CPB was observed, with total body clearance of proprano-
lol unchanged. Conversely, atenolol pharmacokinetics was
not significantly affected by CPB (Table 2). No relationship
was found between the duration of CPB or temperature
during CPB and the pharmacokinetic parameters.
Propranolol, a nonselective β-adrenoceptor blocking
agent, is a lipophilic drug, almost totally absorbed after oral
administration. It has an extensive first-pass effect and
only about 30% of active drug reaches the systemic circu-
lation. Inter-individual variation in the presystemic elimina-
tion of the drug contributes to the wide range of plasma
concentrations detected after oral dosing. Propranolol is a
high extraction drug, extensively biotransformed by the
liver, and most of its metabolites are excreted in the urine.
The biological β half-life and plasma clearance of propran-
olol depend on hepatic blood flow, and thus, they may
change when co-administered with other drugs that affect
propranolol metabolism and hepatic blood flow (15). Fur-
thermore, the biological β half-life of propranolol could
have been prolonged as a consequence of hypothermic
CPB, since it is well known that CPB can decrease protein
plasma drug binding. In the present study, significant in-
creases in unbound drug can explain the apparent volume
of distribution increase in the same relative amount as the
increase in the elimination half-life.
In contrast, atenolol is a long-acting, selective β1-
adrenergic cardiac receptor antagonist and after oral ad-
ministration, despite the lack of presystemic elimination,
about 50 to 60% of the dose is absorbed by the gas-
trointestinal tract and reaches the blood circulation, with
the peak plasma concentration being reached within 2 to 4
h. Due to its high water solubility, atenolol is minimally
metabolized by the liver and is almost completely excreted
in unaltered form into the urine through glomerular filtra-
tion, with a linear correlation demonstrable between atenolol
clearance and glomerular filtration rate.
The aromatic ring of the β-blocker is responsible for the
different lipophilicities of the drug molecule and, pharma-
cokinetically, this influences its protein binding, hepatic
extraction ratio and volume of distribution (16). Proprano-
lol binds to plasma proteins more than atenolol, and ap-
proximately 90% of the circulating drug is bound mainly to
plasma α1-acid glycoprotein (17), with a volume of distribu-
tion of 4.30 L/kg. In contrast, atenolol shows an apparent
volume of distribution of 0.95 L/kg and less than 5%
binding to plasma proteins.
The utilization of hypothermic CPB during CABG in-
duced alterations in propranolol pharmacokinetics not ob-
served in the pharmacokinetics of atenolol. Acute hemodi-
lution, altered plasma protein binding, hypotension, hypo-
thermia, and rewarming are some of the factors that may
change pharmacokinetic properties of propranolol during
the intra-operative period and may have important implica-
tions in the postoperative period. Immediately after starting
CPB, there is a decrease in the plasma concentrations of
propranolol, associated with the direct result of hemodilu-
tion due to CPB priming volume and to a 40-50% decrease
in plasma protein levels (18). The decrease in plasma
proteins may compensate the direct effect of hemodilution
on plasma drug concentration by increasing the free drug
fraction. For drugs with strong binding to plasma proteins,
such as propranolol, hemodilution results in a possible
relatively larger increase in the free fraction. This could,
therefore, result in a greater transfer of the drug out of the
blood/prime mixture to the tissues, and thus a lower total
concentration in the blood/prime mixture (19). The de-
crease in plasma proteins may persist after CPB and an
increase in the plasma free fraction of propranolol would
be expected in the postoperative period.
Although β-blockers reduce the incidence of all-cause
deaths and sudden cardiac death after myocardial infarc-
tion (2), as well as blunting the hemodynamic responses to
surgical stimulation when administered preoperatively and
also reducing preoperative events among high-risk pa-
tients undergoing major noncardiac and vascular surgery
(8,20), few studies have examined whether β-blocker thera-
py is beneficial when used preoperatively in patients un-
dergoing CABG (21). Extrapolation of the cardioprotective
benefits of β-blockers from major noncardiac and vascular
settings to cardiac surgery is reasonable, but there is
concern that this treatment, when applied to CABG pa-
tients, may be detrimental due to depression of myocardial
contractility and/or exacerbation of underlying reactive
airway disease. Ferguson et al. (21) analyzed the Society
of Thoracic Surgeons National Adult Cardiac Surgery Da-
tabase from 1996 to 1999 to examine patterns of preopera-
tive use of β-blockers in patients undergoing isolated CABG
and concluded that preoperative β-blocker therapy, used
in 50-60% of patients, was associated with a small but
consistent survival benefit for patients undergoing CABG,
except for patients with a poor left ventricular ejection
fraction.
After the studies of Boudoulas et al. (7,22), the mainte-
nance of preoperative β-blocker therapy became a routine
procedure, since it does not modify myocardial perfor-
mance during the pre- and posthypothermic CPB period.
Furthermore, due to the markedly increased adrenergic
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tone on the day before the surgery and the transient
hypersensitivity to adrenergic stimulation after withdrawal
of propranolol, this agent should be continued until the day
before coronary bypass surgery and should be reintro-
duced in the postoperative period as soon as possible.
However, according to the present results, an accumula-
tion of propranolol might be expected in patients undergo-
ing CABG under hypothermic CPB.
The changes in pharmacokinetic parameters of pro-
pranolol observed in the present study indicate a prolonga-
tion of biological β half-life and a 2-fold increase in volume
of distribution after surgery. These alterations in proprano-
lol pharmacokinetics may be responsible for the decrease
in the dose required for adequate β-blockade effects in the
postoperative period.
Organ perfusion alterations caused by CPB and hypo-
thermia influence the metabolism and elimination of the
drug by the liver and kidneys (23,24). However, in the
present study, we cannot assume that the effects of CPB
on liver and kidney function played a major role in the
changes observed in the pharmacokinetics of propranolol,
since the plasma clearance was unchanged. No correla-
tion was observed between the duration of CPB or temper-
ature and the changes in propranolol biological β half-life,
volume of distribution or total plasma clearance but there
was a strong correlation between the increase in biological
β half-life and volume of distribution. These results also
argue in favor of hemodilution and a possible decrease in
plasma proteins as the main mechanisms responsible for
the changes demonstrated here in the pharmacokinetic
parameters of propranolol observed during the postopera-
tive period. More studies comparing propranolol pharma-
cokinetics in patients undergoing CABG with CPB to off-
pump CABG are necessary to further investigate the spe-
cific roles of CPB-induced hemodilution and decreased
plasma proteins.
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